Biosyntech

Laval, Canada Founded: 1994 • Age: 32 yrs Acquired By Piramal Group
Biotherapeutic thermogels are developed for tissue repair applications.
Annual revenue - Latest available
Total funding $1.4M 1 rounds
Employees - Tracked headcount
Investors 5 Known backers
Products - Services tracked
Competitors 11 Brand Intelligence

About Biosyntech

Biosyntech is a company based in Laval (Canada) founded in 1994 was acquired by Piramal Group in June 2010. Biosyntech has raised $1.4 million across 1 funding round from investors including Piramal Group, ProQuest Investments and Highland Capital Partners. Biosyntech operates in a competitive market with competitors including Augmenix, AmacaThera, QBiotics, MediWound and Ilya Pharma, among others.

  • Headquarter Laval, Canada
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Medical Devices & Diagnostics
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $1.4 M (USD)

    in 1 rounds

  • Latest Funding Round
    $1.4 M (USD), Series A

    Jun 01, 2009

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Piramal Group

    (Jun 22, 2010)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Biosyntech

Biosyntech has successfully raised a total of $1.4M through 1 strategic funding round. The most recent funding activity was a Series A round of $1.4 million completed in June 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Series A — $1.4M
  • First Round

    (01 Jun 2009)

  • Investors Count 4
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2009 Amount Series A - Biosyntech Valuation

investors

Investors in Biosyntech

Biosyntech has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Piramal Group, ProQuest Investments and Highland Capital Partners.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
Venture capital investment and entrepreneur support services.
Founded Year Domain Location
VC firm focusing on life science sector
Founded Year Domain Location

Investments & Acquisitions by Biosyntech

Investments

Financial Statements - Biosyntech

Biosyntech Comparisons

+
Add Comparison
Available on Premium

Competitors of Biosyntech

Biosyntech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Augmenix, AmacaThera, QBiotics, MediWound and Ilya Pharma, among others.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Hydrogel spacers are provided for prostate cancer radiation therapy.
domain founded_year HQ Location
Injectable hydrogel platform developed for therapeutic medical applications.
domain founded_year HQ Location
Small molecules from plant extracts are developed for medical applications.
domain founded_year HQ Location
Enzymatic therapies for tissue repair and regeneration are developed.
domain founded_year HQ Location
Biological drugs for skin and mucosa wound treatment are developed.
domain founded_year HQ Location
Macrophage cell therapies are developed for inflammatory and liver diseases.

Latest news on Biosyntech

Frequently Asked Questions about Biosyntech

Biosyntech was founded in 1994 and raised its 1st funding round 15 years after it was founded.

Biosyntech is headquartered in Laval, Canada. It is registered at Laval, Quebec, Canada.

Biosyntech is a funded company, having raised a total of $1.4M across 1 funding round to date. The company's 1st funding round was a Series A of $1.4M, raised on Jun 01, 2009.

BioSyntech was founded in 1994 in Laval, Canada, as a biotechnology firm. Chitosan-based hydrogels, known as BST-Gel, were developed for cartilage repair and therapeutic agent delivery. These thermogels, liquid at low temperatures and solid at body temperature, were designed for injection or application to sites like damaged cartilage, bone, and chronic wounds. Bankruptcy was filed in May 2010, followed by acquisition by Piramal Healthcare in June 2010.

Biosyntech's top competitors include Ilya Pharma, AmacaThera and Augmenix.

Biosyntech has 5 investors. Key investors include Piramal Group, ProQuest Investments, Highland Capital Partners, Fonds de solidarite FTQ, and Pappas Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available